Among other changes in Big Pharma manufacturing networks includes AstraZeneca's construction of a new $150-million manufacturing
facility in the Kaluga region in Russia. In June 2011, the company also announced plans to establish a Predictive Science
Center in St. Petersburg. In addition, AstraZeneca has established several partnerships with Russian development institutes,
including the Skolkovo Innovation Centre and Russia Venture Company. In China, Eli Lilly is building a second manufacturing
plant and dedicated diabetes research center. Earlier this year, Boehringer Ingelheim acquired the rights and substantially
all the assets at Amgen's Fremont, California, development and manufacturing facility. The Fremont site includes a 100,000-ft2 manufacturing facility with a pilot plant and process-development laboratories. Boehringer Ingelheim will use the facility
to enhance its contract-manufacturing activities. The company has been a contract manufacturer for Amgen.